智通财经网·2025-09-10 06:14Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant stock price increase of over 41% in the afternoon trading session, with a cumulative rise exceeding 80% post-earnings announcement, despite reporting a substantial decline in revenue and an increase in shareholder losses [1] Financial Performance - The company reported a revenue of 14.529 million Singapore dollars, representing a year-on-year decrease of 43.98% [1] - Shareholder losses amounted to 10.253 million Singapore dollars, which is a year-on-year increase of 69.67% [1] Capital Raising and Use of Proceeds - The company announced a plan to issue 120 million new shares, which will represent approximately 2.27% of the enlarged share capital [1] - The net proceeds from this issuance are expected to be around 161 million Hong Kong dollars, intended for potential acquisitions in the healthcare sector, research and development expenses, and general working capital [1] Strategic Partnerships - On July 2, the company's wholly-owned subsidiary, Shanghai Jin Hai Medical Technology Co., Ltd., entered into a five-year cooperation framework agreement with Ningbo David Medical Instruments Co., Ltd. [1] - This agreement aims to collaborate on endoscope products in the international market, focusing on creating competitive high-end medical device solutions [1]